Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-year open-label deferasirox trial in transfusion-dependent iron overload
2004-003953-16Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deferasirox in transfusional hemosiderosis, sponsored by Novartis. Primary endpoint: Change in serum ferritin from baseline to 52 weeks. Started Apr 2005; status: completed.
02
Drugs
deferasirox
03
Conditions
transfusional hemosiderosis
Beyond the preview
Go deeper on 2004-003953-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003953-16.